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In the Lancet HIV, Markowitz et al. report the ECLAIR study assessing the safety 
and pharmacokinetics of the cabotegravir long-acting (CAB-LA) injections.1  CAB-
LA has been shown to prevent simian HIV infection following repeated rectal 
challenges,2 and to provide high efficacy following repeated vaginal challenges.3  
These challenge studies suggest that integrase inhibitors alone can act as pre-
exposure prophylaxis (PrEP) even though integration is a later step in the HIV 
life-cycle.  In combination with long-acting rilpivirine, CAB-LA is also a promising 
HIV treatment approach to maintain viral suppression after induction with oral 
agents.4  Considerable hope centres on the long-acting injections, as adherence to 
oral daily tenofovir/emtricitabine (TDF/FTC) PrEP  has been low in some 
populations.5  Long-acting injections for contraception have proved popular with 
users and public health programmes worldwide, and offering different 
modalities has increased uptake.  Importantly, Markowitz et al. show that drug 
exposure in HIV-negative men who received 800mg of CAB-LA in two 2mL 
injections administered into the gluteal muscles every 12 weeks differed from 
predictions derived from mathematical models.  Maximum concentrations were 
higher and trough concentrations lower than expected.  As a consequence, the 
efficacy study is assessing single 3mL injections of 600mg of CAB-LA every eight 
weeks after two injections four weeks apart.6  The injection phase is 52 weeks 
long, preceded by five weeks of oral cabotegravir or TDF/FTC, and followed by 
48 weeks of TDF/FTC to minimise the risk of acquiring HIV during the long 
period in which cabotegravir is eliminated.  Radzio et al. presented data at the 
2017 Conference on Retroviruses and Opportunistic Infections on CAB-LA 
initiation in macaques with acute HIV infection, showing that mutations 
associated with resistance to integrase inhibitors (including G118R, E92Q, E92G) 
were selected.  Some of these mutations were detected as early as eight weeks, 
persisted during the pharmacologic tail, and were detected in rectal and vaginal 
fluids, highlighting the potential for secondary transmission of these resistant 
viruses.7  Injection site reactions were common in the CAB-LA group in the 
ECLAIR study, and may increase in severity with the larger injection volume. If 
this leads to discontinuation of product in the efficacy trial, the proportion 
completing the injection schedule may be even lower than the 82% reported by 
Markowitz.  Nonetheless, if efficacy and acceptability are confirmed to be high, 
then there may be a substantial market demand in countries where injectables 
are common. 
 
There is much to celebrate about the science of PrEP and the size of the pipeline, 
but we remain dismayed by the slow roll-out.  In spite of two randomised 
controlled trials showing that TDF/FTC was highly effective at reducing HIV in 
men who have sex with men (MSM) in the UK and France8, 9 and market 
authorisation, only two European countries have implemented a PrEP 
programme.  Public health authorities cite the costs of the drug and PrEP 
delivery as the two most substantial barriers.10  Uncertainty remains regarding 
the date when generic combinations of TDF/FTC will become available in 
Europe.  Generic manufacturers have challenged the intellectual novelty of 
Gilead’s formulation, and the case is in the queue for the European Court of 
Justice.  If the court finds in favour of the generic companies the cost of PrEP 
could be accommodated within current budgets through the savings made in 
treatment costs.  Over 800 MSM have purchased PrEP via the internet and use 
our routine service to screen for HIV and sexually transmitted infections (STIs).11 
We saw a substantial decrease in the number of new HIV infections in 2016 in 
this population.12  The fact that we still have no national programme to assist 
those who cannot afford to purchase their own PrEP is testimony to the 
complexity of evidence required to shift policy.  We have to hope that this is 
resolved by the time we have efficacy data for CAB-LA.  
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